Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance-Reference-Cited by-同舟云学术

Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance

Published:2008-01-23 Issue:2 Volume:29 Page:217-233
ISSN:0163-769X
Container-title:Endocrine Reviews
language:en
Short-container-title:

Author:

Arpino Grazia¹²,Wiechmann Lisa³¹²,Osborne C. Kent³¹²⁴,Schiff Rachel³¹²⁴

Affiliation:

1. The Dan L. Duncan Cancer Center (G.A., L.W., C.K.O., R.S.), Baylor College of Medicine, Houston, Texas 77030

2. The Department of Medicine (G.A., L.W., C.K.O., R.S.), Baylor College of Medicine, Houston, Texas 77030

3. Lester and Sue Smith Breast Center (L.W., C.K.O., R.S.), Baylor College of Medicine, Houston, Texas 77030

4. The Department of Molecular and Cellular Biology (C.K.O., R.S.), Baylor College of Medicine, Houston, Texas 77030

Publisher

The Endocrine Society

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://academic.oup.com/edrv/article-pdf/29/2/217/8862957/edrv0217.pdf

Reference178 articles.

1. Tamoxifen for early breast cancer: an overview of the randomised trials.;Group;Lancet,1998

2. Tamoxifen—what next?;Gradishar;Oncologist,2004

3. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.;Fisher;J Natl Cancer Inst,1998

4. Aromatase inhibitors: future directions.;Osborne;J Steroid Biochem Mol Biol,2005

5. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.;Johnston;Clin Cancer Res,2003

Cited by 452 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 27-hydroxycholesterol induces multidrug resistance in estrogen receptor- positive breast cancer cells via elevation of HER2;2024-09-11

2. ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance;Cancer Letters;2024-09

3. Prognosis in HR-positive metastatic breast cancer with HER2-low versus HER2-zero treated with CDK4/6 inhibitor and endocrine therapy: a meta-analysis;Frontiers in Oncology;2024-08-29

4. ERBB2/HOXB13co-amplification with interstitial deletion ofBRCA1defines a unique subset of breast cancers;2024-08-07

5. Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer;Cancers;2024-07-24